Pre-ALLHAT Drug Use IMS Health NDTI, 1978-1992 0 10 20 30 40 50 60 1978 Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.

Slides:



Advertisements
Similar presentations
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in.
Advertisements

JNC 8 Guidelines….
ASCOT ASCOT STUDY. ASCOT INTRODUCTION AND AIMS EXISTING KNOWLEDGE BACKGROUND OF ASCOT STUDY DESIGN (TWO ARMS (BPLA,LLA) METHODOLOGY TREATMENT REGIMES.
11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
Valsartan Antihypertensive Long-Term Use Evaluation Results
ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Hypertension: what is new…and old GREG FOTIEO, MD.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Improving the Care of the Hypertensive Patient: US Perspective William Cushman, MD Professor, Preventive Medicine and Medicine University of Tennessee.
1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
1 Setting the Record Straight ALLHAT. 2 Major ALLHAT Findings CHD risk not improved for any of the 3 newer agents compared with chlorthalidone Total mortality.
DR. IDOWU AKOLADE EDM DIVISION LUTH
Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid- lowering Treatment to Prevent Heart.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
1 U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Major Outcomes in High Risk Hypertensive.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.
1 Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial ALLHAT Davis.
1 Can One Evaluate An Outcomes Claim Based On An Active Controlled Study? Pfizer Response Cardiovascular and Renal Drugs Advisory Committee Rockville,
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
1 Current & New treatment strategies to address CV Risk.
HvC Comparative Effectiveness Project Groups 5 and 6
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute ALLHAT Major Outcomes in Moderately.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
Thiazide diuretics, Potassium, and the Development of Diabetes A Quantitative Review Hypertension2006_219.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
Is there evidence to justify different claims for different drug classes? Presentation to: Cardiovascular & Renal Drugs Advisory Committee Food & Drug.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
CCB in Management of Hypertension in Older Persons Presented by Mona Ahmed sherif Marwa Shaaban Shimaa Adel Ahmed Salma Sadek Alia khalid.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).
Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr.
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
Management of Hypertension according to JNC 7
Hypertension JNC VIII Guidelines.
Health and Human Services National Heart, Lung, and Blood Institute
Copyright © 2000 American Medical Association. All rights reserved.
ALLHAT ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status.
The Anglo Scandinavian Cardiac Outcomes Trial
Why wasn’t a beta-blocker tested as first-line therapy?
The following slides highlight a presentation at the Hotline Session of the European Society of Cardiology Annual Congress, September 3-7, 2005 in Stockholm,
Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.
Progress and Promise in RAAS Blockade
ALLHAT: What Outcomes Would Have Been Expected?
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.
Health and Human Services National Heart, Lung, and Blood Institute
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Originally presented by Drs. Daniel Levy, Richard H. Grimm, Steven E
Post-Heart Failure Mortality
The following slides highlight a report by Dr
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.
Presentation transcript:

Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors CCBs ß-Blockers Diuretics

Background In addition to their BP lowering potential all antihypertensive agents have other important mechanisms of action, indications, and side effects.In addition to their BP lowering potential all antihypertensive agents have other important mechanisms of action, indications, and side effects. These actions may convey benefits or risks independent of BP loweringThese actions may convey benefits or risks independent of BP lowering By having a common BP goal for all treatment arms, ALLHAT aimed to evaluate the health effects of these non-BP actionsBy having a common BP goal for all treatment arms, ALLHAT aimed to evaluate the health effects of these non-BP actions ALLHAT

Overall Purpose To determine whether the newer, more costly antihypertensive drugs - CCBs, ACE inhibitors and alpha-blockers - are superior to the older, less expensive diuretics in preventing CV complications of hypertension. ALLHAT

Health Effects of Diuretics Low-dose thiazide-type diuretic-based treatment in large clinical trials has been shown to reduce the risks of: Event reduction % Stroke 34 Heart failure 42 CHD 28 CVD mortality 24 Total mortality 10 ALLHAT Psaty et al., JAMA 1997;277:739-45

Strengths Largest hypertension trial ever (n=42,418); practice-basedLargest hypertension trial ever (n=42,418); practice-based Diverse study populationDiverse study population High methodologic standardsHigh methodologic standards Independent sponsorship and conductIndependent sponsorship and conduct Conclusions based on 10,834 cardiovascular eventsConclusions based on 10,834 cardiovascular events ALLHAT

Implications 1.Selection of first-line drug 2.Selecting treatments for particular patients 3.Drug cost and health benefit ● To patients ● To society 4.Design of future hypertension trials 5.Impact on treatment guidelines ALLHAT

Selection of 1 st -line Drug - Conclusions Among antihypertensive drugs, thiazide- like diuretics were unsurpassed in: long-term drug adherencelong-term drug adherence controlling elevated blood pressurecontrolling elevated blood pressure and were superior to other therapies in preventing one or more forms of cardiovascular eventspreventing one or more forms of cardiovascular events having lower drug costhaving lower drug cost ALLHAT Implications

Selection of 2 nd -line Drug(s) - Type of Add-on Large proportion of hypertensive patients require additional drug(s) for BP controlLarge proportion of hypertensive patients require additional drug(s) for BP control No direct comparison of 2 nd -line drugs in ALLHATNo direct comparison of 2 nd -line drugs in ALLHAT Optimal type of add-on agent unknownOptimal type of add-on agent unknown Need for large trials comparing different classes of agents added to diureticsNeed for large trials comparing different classes of agents added to diuretics ALLHAT Implications

Source: NDTI -- IMS HEALTH 2002 Use of Antihypertensive Medications, Proportion of Drug-Treated Patients by Drug Class 0% 10% 20% 30% 40% ACE- Inhibitors Calcium Channel Blockers DiureticsBeta- Blockers ARBs % Patients 37% 27% 20% 20% 19%

Selecting Treatments for Particular Patients I Benefits of diuretics generalizable to: Men and womenMen and women Age group 65 yrsAge group 65 yrs Blacks and non-blacksBlacks and non-blacks Diabetics and non-diabeticsDiabetics and non-diabetics Presence and absence of other co- morbidityPresence and absence of other co- morbidity ALLHAT Implications

Diuretics are better than: -ACEIs (lisinopril) for patients at high risk of CVD events, especially heart failure, as well as for African-Americans at risk of stroke -Alpha-blockers (doxazosin) for patients at high risk of heart failure, stroke, angina and coronary revascularizations -CCBs (amlodipine) for patients at high risk of developing heart failure ALLHAT Implications Selecting Treatments for Particular Patients II

Selecting Treatments for Patients - Conclusions Thiazide-type diuretics should be considered for nearly all patients with hypertension: Untreated patientsUntreated patients Inadequately controlled patients on non-diuretic agent(s)Inadequately controlled patients on non-diuretic agent(s) Controlled patients on non-diuretic agent(s) unless compelling indication exists for another agentControlled patients on non-diuretic agent(s) unless compelling indication exists for another agent ALLHAT Implications

Drug Cost to Patient (U.S. 2002) Chlorthalidone$ 36 Amlodipine$679 Lisinopril- branded$533 - generic**$280 *Drugstore.com (exclusive of dispensing fee) **available 3 rd quarter 2002 Annual Implications ALLHAT

Drug Cost to Society ACEIs$ $3, , ,769 CCBs$ $6,315 Diuretics$ $ 248 ALLHAT Average Annual AnnualDrugCost/Pt* No. of AnnualUsers** TotalDrugCost** *price of largest selling drug/class (2002) **in million Implications

Excess CV Events ACEIs Comb CV 2.3% ,700 EventsCCBs CHF 2.5% ,800 ALLHAT 6-yrExcess TotalUsers* Excessevents/yr** *in million**concomitant use of diuretics may reduce these numbers by up to 20% Implications

Design of Hypertension Trials Thiazide-like diuretics, in low to moderate dose, should be the treatment control group of future comparative trials in patients with hypertension. ALLHAT Implications

Treatment Guidelines Thiazide-like diuretics, in low to moderate dose, should be the guideline-recommended first-line drug treatment for nearly all patients with hypertension. ALLHAT Implications

Conclusions I The benefit of diuretics as first-line therapy applies to nearly all patients with hypertensionThe benefit of diuretics as first-line therapy applies to nearly all patients with hypertension Diuretics are superior or unsurpassed in reducing the risks of cardiovascular complicationsDiuretics are superior or unsurpassed in reducing the risks of cardiovascular complications Diuretics are the least expensive agents for treating hypertensionDiuretics are the least expensive agents for treating hypertension ALLHAT Implications

Conclusions II Translating the ALLHAT findings into practice will reduce the financial cost of antihypertensive drugs and reduce the societal burden of CV complicationsTranslating the ALLHAT findings into practice will reduce the financial cost of antihypertensive drugs and reduce the societal burden of CV complications Future comparative hypertension trials should use diuretics as the control group or base therapyFuture comparative hypertension trials should use diuretics as the control group or base therapy Treatment guidelines are being revised to reflect the ALLHAT findingsTreatment guidelines are being revised to reflect the ALLHAT findings ALLHAT Implications